A small-molecule compound, GSK2194069, specifically inhibits the β-ketoacyl reductase (KR) activity of the human fatty acid synthase. A co-crystal structure of the KR domain with the inhibitor confirms this interaction.
- Mary Ann Hardwicke
- Alan R Rendina
- Cynthia A Parrish